Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

NCT03446144 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business objective change, no safety or efficacy concerns

Conditions

Geographic Atrophy
Age Related Macular Degeneration

Interventions

DRUG: IONIS-FB-Lrx
DRUG: Placebo (sterline saline 0.9%)

Sponsor

Ionis Pharmaceuticals, Inc.